

A randomised trial of intravesical irrigation in superficial bladder cancer followed by treatment with epodyl or mitomycin C at the time of first recurrence

Submission date 13/03/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 13/03/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 19/02/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Danielle Andrews

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Additional identifiers

Protocol serial number
BS04

Study information

Scientific Title

A randomised trial of intravesical irrigation in superficial bladder cancer followed by treatment with epodyl or mitomycin C at the time of first recurrence

Study objectives

1. To detect the reduction, if any, of recurrence following irrigation of the bladder with glycine following complete resection of newly diagnosed bladder cancer
2. To compare the effect of Mitomycin-C against Epodyl in patients who develop recurrent superficial tumour following the initial transurethral resection in preventing further recurrence

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Bladder cancer

Interventions

Epodyl or mitomycin C

Follow-up: 3 monthly for 1st year, 6 monthly for 2nd year, annually thereafter.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Epodyl or mitomycin C

Primary outcome(s)

Recurrence free survival

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/12/1995

Eligibility

Key inclusion criteria

1. Newly diagnosed superficial bladder cancer suitable for complete endoscopic resection
2. Transitional cell carcinoma limited to the bladder, no evidence of carcinoma in the upper tracts
3. World Health Organisation (WHO) performance status 0-2
4. Expected survival at least 3 years
5. White count greater than $3 \times 10^9/L$ and platelets greater than $100 \times 10^9/L$
6. No untreated urinary tract infection

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/07/1987

Date of final enrolment

01/12/1995

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)**Funder type**

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration